Eric Jonasch, MD
M.D. Anderson Cancer Center
Emerging Leaders
not ranked
Current Leaders
#4242 pts
All-Time Leaders
#2,41514 pts
Scored by the scientific impact (publications, citations, press) of the trials they lead, weighted by role. First trial 2005. 9 trials as lead/chair. How it works →
Trials led — by scientific impact
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
Phase 2RecruitingM.D. Anderson Cancer Center
3
impact
A Phase II Clinical Trial to Evaluate the Efficacy of BAY 43-9006 With or Without Low Dose Interferon in Metastatic Renal Cell Carcinoma
Phase 2CompletedNational Cancer Institute (NCI)
3
impact
Phase II Non-Randomized Pre-Surgical Study Evaluating Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC) Who Are Eligible for Cytoreductive Nephrectomy
Phase 2ActiveM.D. Anderson Cancer Center
3
impact
A Phase II Study of Alternative Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma (mRCC)
Phase 2CompletedM.D. Anderson Cancer Center
2
impact
A Phase 2 Study of SU011248 (Sunitinib Malate) in Von Hippel-Lindau Syndrome
Phase 2TerminatedM.D. Anderson Cancer Center
1
impact
Phase II Study of Carfilzomib in Patients With Refractory Renal Cell Carcinoma
Phase 2CompletedM.D. Anderson Cancer Center
1
impact
A Pilot Trial of TKI 258 (Dovitinib) in Von Hippel-Lindau Syndrome
Phase 2TerminatedM.D. Anderson Cancer Center
1
impact
A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)
Phase 2RecruitingM.D. Anderson Cancer Center
1
impact
A Phase II Trial of Pazopanib in Von Hippel-Lindau Syndrome
Phase 2CompletedM.D. Anderson Cancer Center
0
impact
A Phase II Neoadjuvant Clinical Trial to Evaluate the Efficacy of BAY 43-9006 (Sorafenib) in Metastatic Renal Cell Carcinoma
Phase 2TerminatedNational Cancer Institute (NCI)
0
impact
A Phase II Neoadjuvant Clinical Trial to Evaluate the Efficacy of Recombinant Humanized Monoclonal Anti-VEGF Antibody rhuMab VEGF (Bevacizumab) for Renal Cell Carcinoma
Phase 2CompletedM.D. Anderson Cancer Center
0
impact
A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)
Phase 1RecruitingM.D. Anderson Cancer Center
0
impact
Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)
Phase 2RecruitingM.D. Anderson Cancer Center
0
impact
Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)
Phase 2RecruitingM.D. Anderson Cancer Center
0
impact
A Multi-center, Open-label Phase II Study of Lenvatinib Plus Pembrolizumab (LEAP) in Renal Cell Carcinoma Patients With Brain Metastasis Previously Treated With Immune Checkpoint Blockade
Phase 2WithdrawnM.D. Anderson Cancer Center
0
impact
A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)
Phase 2ActiveM.D. Anderson Cancer Center
0
impact
Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.
Phase 2ActiveM.D. Anderson Cancer Center
0
impact
A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma
Phase 2TerminatedNational Cancer Institute (NCI)
0
impact
A Phase II Metastasectomy Study for Patients With Renal Cell Carcinoma
Phase 2ActiveM.D. Anderson Cancer Center
0
impact